Filing Flows › Caris Life Sciences (CAI) › Q3 2026 › vs Q2 2026
Caris Life Sciences (CAI) Q3 2026 vs Q2 2026 (quarter over quarter)
Caris Life Sciences's revenue rose $11.6M (+4%) from $264M in Q2 2026 to $275M in Q3 2026. The biggest changes: Molecular Profiling Services +$10.5M (+4%); Pharma Research and Development Services +$1.2M (+10%). Operating margin 7.0% against 10.2% (-3.2 pts).
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 7.0% | 10.2% | -3.2 pts |
| Net margin | 5.5% | -0.2% | +5.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Molecular Profiling Services | $263M | $252M | $10.5M | +4% |
| Pharma Research and Development Services | $12.7M | $11.5M | $1.2M | +10% |
| Revenue | $275M | $264M | $11.6M | +4% |
| Operating profit | $19.3M | $26.9M | −$7.6M | -28% |
| Costs & expenses | $256M | $237M | $19.3M | +8% |
| Pre-tax earnings | $16.9M | −$614K | $17.5M | — |
| Other expense, net | $2.4M | $27.5M | −$25.1M | -91% |
| Research & development | $33.8M | $32.4M | $1.5M | +5% |
| Sales & marketing | $59.9M | $53.8M | $6.1M | +11% |
| General & admin | $69.3M | $66.5M | $2.7M | +4% |
| Other operating costs | $93.1M | $84.1M | $9.0M | +11% |
| Net earnings | $15.2M | −$637K | $15.9M | — |
| Income tax | $1.6M | $23K | $1.6M | 71× |
| Operating cash sources | $62.6M | −$395K | $63.0M | — |
| Depreciation & amortization | $6.6M | $6.5M | $100K | +2% |
| Share-based compensation | $18.5M | $22.2M | −$3.7M | -17% |
| Cash used in operations | $22.2M | −$28.5M | $50.7M | — |
| Working capital & other | $62.6M | −$395K | $63.0M | — |
Questions
How much did Caris Life Sciences's revenue grow quarter over quarter in Q3 2026?
Caris Life Sciences's revenue rose $11.6M (+4%) from $264M in Q2 2026 to $275M in Q3 2026.
What drove Caris Life Sciences's revenue change in Q3 2026?
Molecular Profiling Services +$10.5M (+4%); Pharma Research and Development Services +$1.2M (+10%).